

1 **Onset, duration, and persistence of taste and smell changes**
2 **and other COVID-19 symptoms: longitudinal study in Israeli**
3 **patients**

4

5 Hadar Klein^{1#}, Kim Asseo^{1#}, Noam Karni^{2#}, Yuval Benjamini³, Ran Nir-Paz⁴, Mordechai
6 Muszkat², Sarah Israel^{2§}, Masha Y. Niv^{1§*}

7

8 #equal contributions as first authors

9 §equal contributions as senior authors

10 *corresponding author

11 ¹The Institute of Biochemistry, Food and Nutrition, The Hebrew University, Rehovot, Israel

12 ²Department of Medicine, Hadassah University Hospital, Mt. Scopus Campus, Jerusalem, Israel

13 ³Department of Statistics, The Hebrew University, Mt. Scopus Campus, Jerusalem, Israel

14 ⁴Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University medical
15 center

16

17 **KEYWORDS:**

18 COVID-19; smell change; taste change; symptoms duration; disease course; recovery;
19 symptoms persistence

20

21 **CORRESPONDING AUTHOR:**

22 Prof. Masha Y Niv, PhD

23 Chemical Senses and Molecular Recognition Lab

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Robert H. Smith Faculty of Agriculture, Food and Environment, Rehovot, Israel

25 The Hebrew University of Jerusalem, Israel

26 E-mail: masha.niv@mail.huji.ac.il, Tel: +972-89489664

27

28 **ABSTRACT**

29 **Objectives:** The multifaceted disease manifestation of COVID-19 requires longitudinal
30 characterization of symptoms, to aid with screening and disease management.

31 **Methods:** Phone interviews and follow-ups were completed with 112 mild COVID-19
32 RT-PCR-positive adult patients, over a six weeks period.

33 **Results:** More than one symptom at disease onset was experienced by ~70 of the
34 patients. Over one third of the patients experienced fever, dry cough, headache, or
35 muscle ache as the first symptom. If fatigue was reported, it was usually the first
36 symptom to appear. Smell and taste changes had occurred 3.9 ± 5.4 and 4.6 ± 5.7 days
37 (mean \pm SD) since disease onset and emerged as first symptoms in 15% and 18% of
38 patients, respectively. Fever was the shortest lasting symptom (5.8 ± 8.6 days (mean
39 \pm SD), and smell and taste changes were the longest-lasting symptoms (24.3 ± 22.9
40 days and 19.4 ± 19.1 (mean \pm SD), respectively), with longer smell recovery correlated
41 with smell change severity. In one third of patients who reported cough, smell and
42 taste changes, these symptoms persisted after negative RT-PCR tests.

43 **Conclusions:** Each symptom can occur as first or later, some are more likely to appear
44 as firsts, and typically more than one symptom occurs at disease onset. The severity
45 of olfactory change is associated with its recovery time. Lack of chemosensory
46 recuperation in recovered patients is common. These findings can aid patients through
47 their illness and provide expected recovery patterns.

48 **BACKGROUND**

49 The coronavirus disease (COVID-19) has become a global pandemic, with more than
50 31 million globally reported cases as of September 24th, 2020 including 972,221 deaths
51 (World Health Organization, 2020). This pandemic resulted in multiple socio-economic
52 implications on a worldwide scale[1]. COVID-19 symptoms and severity vary
53 widely[2,3]. It has been established that COVID-19 can result in prolonged illness even
54 among milder patients[4]. Symptoms may persist post patient recovery, which is
55 usually defined as symptoms improvement along with negative real time polymerase
56 chain reaction (RT-PCR) test results for COVID-19[5].

57 COVID-19 initially targets the human respiratory system, with the most common
58 symptoms according to the Centers for Disease Control and Prevention (CDC) being
59 fever, cough, shortness of breath, fatigue, muscle aches, headache, new loss of smell
60 or taste, sore throat, congestion, nausea/vomiting and diarrhea. Other commonly
61 reported symptoms also include sputum production, hemoptysis and lack of
62 appetite[6,7]. These symptoms' order of appearance, severity, durations and
63 persistence after recovery, is only partly studied[5,8,9].

64 In this study, we address gaps in knowledge regarding the order of symptoms
65 appearance and their durations in RT-PCR positive patients. Establishing COVID-19
66 course of illness in terms of symptoms severity, order of appearance, duration, and
67 persistence after recovery, is of key importance for patients' ability to cope with the
68 mental, social, and financial challenges that accompany the disease.

69

70

71

72 **METHODS**

73 **Aim and setting**

74 This is a follow-up study of patients that participated in our previous study, see Karni
75 and Klein et al.[10], performed in Israel, from April 2020 to May 2020. The study
76 comprised of Israeli residents aged ≥ 18 years with positive COVID-19 RT-PCR results,
77 who were recruited via social media (Twitter and Facebook) and word of mouth for
78 phone interviews. We excluded severely ill patients, and non-Israeli residents.
79 Participants were not screened or targeted for experiencing chemosensory changes.
80 Informed consent was obtained from all participants. The study was approved by the
81 Hadassah Medical Center Helsinki Committee (permit number 0236-20-HMO). Upon
82 agreement to participate, the explanation of the interview, including questions on
83 taste and smell, were read to the participants.

84

85 **General design**

86 The questionnaire was developed in parallel with the Global Consortium for
87 Chemosensory Research, GCCR[11]. The questionnaire[10] had five parts: 1) General
88 information (e.g., age, gender); 2) Medical history (e.g., medical conditions, chronic
89 medications use); 3) Current illness (e.g., 23 physical signs and symptoms, RT-PCR
90 swab test results and dates, subjective recovery feeling); 4 and 5) Smell and taste:
91 Participants were instructed to rate their sense of smell/taste before, during and after
92 their illness, on a scale from 1-10 (1 corresponding to “no sense of smell” and 10 to
93 excellent sense of smell). Data was kept in Compusense Cloud on-line software
94 (Compusense Inc., Guelph, ON, Canada).

95

96 **Patients follow-up**

97 Covid-19 positive patients from our previous Karni and Klein et al. study[10], were
98 followed here to monitor the progress of their illness and recovery. Out of 144 RT-
99 PCR-positive patients, 114 had answered the phone, of which two had missing
100 information regarding rating of chemosensory symptoms, resulting in 112 patients
101 answering the first questionnaire.

102 Recovered patients' category refers to those who received two consecutive negative
103 RT-PCR test results. Patients who either did not recover from their symptoms in the
104 first questionnaire, or did not get two consecutive negative RT-PCR results at the time
105 of answering the first questionnaire, were contacted 3 weeks after the initial
106 interview, for their 3-week follow-up (n=101). If they had not fully recovered at their
107 first follow-up, they were contacted again 3 weeks after their second interview, for
108 their 6-week follow-up (n=46).

109

110 **Data analysis**

111 The participants were asked about 27 symptoms (see web-only Supplementary Figure
112 S1). 7 of these occurred in more than 50% of the patients (Taste change, smell change,
113 fever, dry cough, muscle aches, headache, lack of appetite) and were included in the
114 final analysis. All these symptoms, except lack of appetite, are current official CDC
115 symptoms. Additional 7 symptoms of the less prevalent (<50%) symptoms are the
116 remaining official CDC symptoms (productive cough, shortness of breath, fatigue, sore
117 throat, congestion, nausea/vomiting, and diarrhea), and were therefore also included
118 in the final analysis. "Fatigue" was not explicitly included in the original questionnaire
119 because it was not a known symptom at the time of its drafting, but was nevertheless

120 self-reported in 18% of patients under "any other symptoms" and was therefore
121 included in the final analysis.

122 Disease onset is defined as the first appearance of any of the COVID-19 symptoms
123 described above. Persistent symptoms are defined as symptoms that progress post
124 patient's recovery.

125 Order of appearance and duration were calculated from the dates reported by the
126 participants for each symptom.

127 Severity of smell (taste) change was calculated as the delta between the reported
128 ability to smell before the illness and its reported ability during the illness, rated on a
129 1-10 scale.

130

131 **Statistical analysis**

132 Analyses were conducted using the statistical software R ([https://www.r-](https://www.r-project.org/)
133 [project.org/](https://www.r-project.org/)). Descriptive statistics are presented as the mean and standard deviation.

134 Pearson correlation coefficient was used for testing of correlations. A level of $P < 0.05$
135 was used to determine statistical significance.

136

137 **RESULTS:**

138 **Patients' characteristics**

139 Completed questionnaires were obtained from 112 COVID-19 positive patients. The
140 median age of the respondents was 35 ± 12 years (mean \pm SD) and included (64%)
141 men. 6 patients were classified as hospitalized (received respiratory support during

142 their hospitalization and / or were hospitalized in the intensive care unit) and the
143 remaining 106 were classified as ambulatory patients.

144

145 **Order of symptoms' appearance**


146 Symptoms appearance were usually concomitant: The first and second symptoms to
147 appear were accompanied by additional symptoms in 69% and 45% of the patients,
148 respectively. Headache, fever, dry cough, and muscle aches were the first symptoms
149 to appear in more than one third of the patients (Figure 1A).

150 Smell and taste changes were the first symptoms to appear (either solely or along with
151 other symptoms) in only 15% and 18% of patients, respectively. Fatigue was as a first
152 symptom in majority of patients who reported it(Figure 1A).

153 Headache, fever, dry cough, and muscle aches appeared 1.99 ± 5 , 1.79 ± 4.64 , $1.35 \pm$
154 3.44 and 2.09 ± 5.07 days (mean \pm SD), respectively, after illness onset. Smell and taste
155 changes appeared later, at 3.94 ± 5.45 and 4.58 ± 5.72 days (mean \pm SD), respectively,
156 after illness onset (Figure 1B). Each of the 14 symptoms analyzed here could occur as
157 first or co-first, with vomiting, breathing difficulty and diarrhea being the most spread
158 out in the order in which they appear (see web-only Supplementary Figure S2). Indeed,
159 vomiting and diarrhea appeared after the highest number of days since illness onset
160 (5.57 ± 8.26 and 5.85 ± 9.97 , respectively) (Figure 1B).

A.

Symptom	1 st symptom % of total (% of those who experienced the symptom)	≥2 nd symptom % of total
Headache	43% (70%)	19%
Fever	40% (62%)	25%
Dry cough	38% (62%)	23%
Muscle aches	38% (66%)	20%
Lack of appetite	28% (53%)	25%
Runny nose	20% (51%)	19%
Taste change	18% (25%)	54%
Sore throat	17% (46%)	20%
Smell change	15% (22%)	53%
Productive cough	14% (33%)	29%
Fatigue	14% (80%)	4%
Diarrhea	9% (38%)	14%
Vomit / nausea	6% (30%)	14%
Breath difficulty	4% (25%)	13%



161


162 **Figure 1. Symptoms order. A.** Prevalence of patients for which symptoms appeared
 163 as 1st and ≥2nd symptoms. Symptoms that appeared as 1st in more the third of the
 164 patients are presented with dark background, lower prevalence is presented in light
 165 blue background. **B.** Y axis lists symptoms and X axis shows number of days since illness
 166 started. the mean ± SD number of days for symptom onset is presented for each
 167 symptom. Coloring is according to prevalence, with darkest color indicating most
 168 prevalent symptoms.

169

170 **Distribution of symptoms durations and persistence**

171 Figure 2A depicts the durations of the most prevalent symptoms (>50%) among 112
 172 COVID-19 patients. Fever, lack of appetite, headache and muscle ache had shorter
 173 durations than those of dry cough and changes of taste and smell. In this sample of
 174 patients, the most prolonged symptoms lasted up to 78 days.

175 36% of patients with smell change, 32% of patients with taste change, and 27% with
 176 dry or productive cough, still had these symptoms post recovery (defined as two
 177 consecutive negative RT-PCR-test results) (Figure 2A). Similar results were found also
 178 when recovery is defined as 13 days after symptoms onset, as currently accepted in
 179 Israel (see web-only Supplementary Figure S3). Smell and taste changes duration
 180 present bimodal distributions, with patients who experienced these symptoms as
 181 persistent, comprising the second peak (Figure 2A (6-7)). As seen in Figure 2B,
 182 persistent taste change was usually accompanied by persistent smell change in the
 183 same patient, and in some cases also accompanied by a persistent cough (either
 184 productive or dry). Persistent cough could persist also in patients without persistent
 185 chemosensory change.




186

187 **Figure 2. Symptoms durations and persistence. A. (1-7)** Duration pattern graphs are
188 presented for each symptom and colored according to symptom's persistence post
189 recovery. Y axis shows number of patients (n) and X axis shows duration of symptoms
190 (days). Persistent symptoms are colored purple and symptoms that did not persist are
191 colored pink. Number of patients and the mean \pm SD duration (days) of symptoms is
192 presented for each graph. **B.** Euler-diagram of the most persistent symptoms after
193 recovery. persistent smell and taste changes are marked green and blue, respectively.
194 Cough is marked in seashell color. The number of patients experiencing a symptom as
195 persistent is marked in each circle.

196

197 **Chemosensory recovery patterns**

198 We quantified the level smell and taste recovery during 6 weeks of follow-ups. We
199 found three groups of patients: The 1st group recovered already at the time of the
200 initial interview (their taste and smell ability ratings shown on Figures 3A and 3D). The
201 2nd group of patients were not recovered during initial interview and had one follow-
202 up interview. Figures 3B and 3E show three smell and taste ratings before their illness,
203 at the worst state during their illness and at the time of their second interview. The
204 last group of patients did not recover during the follow-up interview and had a second
205 follow-up. Figures 3C and 3F present four ratings for smell and taste: the score before
206 their illness, at the worst state during their illness, and at the time of second and third
207 interviews. The results indicate full recovery in patients from group 1 and 2, and a
208 slower and gradual recovery of the senses in the last group.



209

210 **Figure 3. Smell and taste ratings over 6-weeks follow-ups. A-C.** Smell scores of
 211 patients recovered at the initial (A), second (B), and third (C) interviews. D-F. Taste
 212 scores of patients recovered at the initial (D), second (E), and third (F) interviews. Y
 213 axis shows rating of smell/taste ability and X axis depicts 5 time points ratings: before,
 214 during and after their illness, rated at initial questionnaire (blue), and at two following
 215 questionnaires (3-weeks (light blue) and 6-weeks (turquoise) follow-ups).

216

217


218

219 **Smell change severity and recovery**

220 We found that the durations of smell and taste were correlated (0.82, $p < 0.001$) (Figure
221 4A), with many patients reporting identical durations for these symptoms.

222 As seen in Figure 4B, a small yet significant correlation was found also between smell
223 change severity and its duration (correlation 0.34, $p = 0.003$). The same was not
224 repeated for taste change severity and its duration (see web-only Supplementary
225 Figure S4).

226 Moreover, it is apparent that some patients' smell change had recovered
227 independently of how severe it was, while for another group of patients, it was closely
228 dependent on its severity (Figure 4B). We did not find any particular characteristics for
229 either of these subgroups.



230

231 **Figure 4. Correlations of smell and taste change characteristics.** A. Correlation of
232 smell and taste change durations (n=67). X axis shows smell change duration and Y
233 axis shows taste change duration (days). B. Correlations between smell change
234 severity and its duration (n=76). X axis shows smell change severity and Y axis shows
235 smell change duration (days).

236

237 **DISCUSSION**

238 Smell and taste changes had emerged as distinctive COVID-19 symptoms[10,12].

239 Considering the importance of chemosensory disorders in COVID-19, it is essential to

240 further study these symptoms in terms of order of appearance in relation to other

241 COVID-19 symptoms, duration, and persistence post recovery.

242 Spinato et al.[13] had found that the time of onset of smell or taste changes was prior

243 to other symptoms in 11.9% of cases and concomitant with other symptoms in 22.8%

244 of cases. In terms of symptoms durations, different reports found that the time for

245 chemosensory recovery is ranging from 8.02 ± 6.41 to 11.6 ± 6.2 days (mean \pm

246 SD)[14,15], others found their persistence post recovery in the range of 20% to 78%

247 of patients[5,16].

248 Our study reveals that smell and taste were the first symptoms to appear, in 15% and

249 18% of cases, respectively, either with or without other symptoms. We found duration

250 of smell change to be 24.3 ± 22.9 days and of taste change to be 19.4 ± 19.1 days

251 (mean \pm SD), and their post-recovery persistence to be prevalent in 36% and 32% of

252 patients, respectively.

253 Concerning other COVID-19 symptoms, we found that even though their order of

254 appearance is varied, headache, fever, dry cough, and muscle aches were often (38%

255 -43%) the first symptoms to appear. Additionally, out of the 18% patients who

256 experienced fatigue, 80% had experienced it as a first symptom (14% of all patients).

257 Of note, the prevalence of fatigue in our study was lower than previously reported

258 36%-46%[17,18], probably because here it was not explicitly part of the questionnaire,

259 but rather self-reported under the "any other symptom" question.

260 Furthermore, we found COVID-19 illness to have a prolonged phase, in which
261 symptoms such as fever, lack of appetite, headache and muscle aches are recovered,
262 but dry cough, taste change and smell change persist, with the latter having the
263 longest duration of 24.3 ± 22.9 days (mean \pm SD). The prolonged phase can persist
264 post-recovery: chemosensory changes were found to persist post recovery in about
265 one third of patients experiencing them (usually by the same patient). Additionally,
266 cough, either dry or productive, was also found to persist in approximately 27% of
267 patients who reported experiencing this symptom. However, patients experiencing
268 cough as persistent can be the same or different than those experiencing persistent
269 chemosensory changes.

270 We found slightly lower prevalence of patients who experienced chemosensory
271 changes as first symptoms than those previously reported[13], which could be due to
272 recall bias caused by retrospective data collection. We also report a lower percentage
273 of persistence post recovery prevalence of smell and taste changes compared to
274 another study [16], which could be due to our larger sample size or other differences.
275 Longer duration of chemosensory changes than those reported by others[14,15,19] is
276 due to the longer follow-ups we conducted. Moreover, our detailed phone interviews
277 did not rely on online surveys, increasing the reliability of the data.

278 Importantly, some surveys did not use scales to determine smell and taste changes
279 and recovery, but rather counted them as binary symptoms[19]. Here we monitored
280 quantitative recovery back to normal levels, possibly accounting for the longer
281 recovery rate we found for the chemosensory changes and higher persistence post-
282 recovery than when binary classification was used[5].

283 We found smell (but not taste) change severity to be correlated with its time to
284 recover. However, while for a group of the patients, the time necessary for their smell
285 change recovery correlated with magnitude of the change they had experienced, for
286 another group, the severity of their smell change was unrelated to the time it took to
287 recover. Such grouping was also reported by Gerkin et al.[12], but characteristics that
288 might account for the differences between these two groups could not yet be
289 unraveled and require future study.

290

291 **Study limitations**

292 Our sample did not include severely ill patients, and therefore is relevant for light to
293 moderately ill patients only. No objective testing was performed, and the information
294 was self-reported by the participants. Additionally, the retrospective data collection
295 method used in this study may have caused recall bias.

296 Our study focuses on a relatively short period (6 weeks) of post-acute illness stage,
297 and future studies of large groups of long lasting and persistent symptoms of COVID-
298 19 during longer periods of time are likely to reveal additional manifestations of “long
299 COVID”[20].

300

301 **Conclusions**

302 We have carefully mapped the start and end dates of various COVID-19 symptoms of
303 112 mild patients in Israel. The results indicate that despite large variability in
304 symptoms onset and duration, some symptoms (headache, fever, dry cough, and
305 muscle aches) are common as first or co-first symptoms. Fatigue, if occurs, usually
306 appears as first. Taste and smell changes are not typically first, and appear on average,

307 3.9 ± 5.4 and 4.6 ± 5.7 days (mean ± SD), respectively, since illness onset. Their
308 recovery can be either fast, or longer and gradual, sometimes accompanied by cough.
309 Interestingly, while dry cough appears early (1.35 ± 3.44 days (mean ± SD)) and
310 productive cough later (4.54 ± 7.09 days (mean ± SD)), both types of cough may persist
311 post recovery. This information regarding their symptoms' durations and persistence
312 post recovery, can potentially reduce anxiety and promote better management of
313 patients financial, social, and mental wellbeing during the disease.

314

315 **Authors' contributions**

316 NK and MYN initiated the research, SI, NK and MM wrote the IRB proposal, NK
317 recruited patients, NK, MYN, YB, SI and MM designed the research, SI, MM, RNP and
318 MYN supervised the research, HK carried out the interviews, HK and MYN drafted the
319 manuscript, KA and YB performed the statistical analysis, KA and HK created figures
320 and tables. All authors contributed to writing and approved the final manuscript.

321

322 References

- 323 [1] Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the
324 coronavirus pandemic (COVID-19): A review. *Int J Surg.* 2020;78:185-193.
325 doi:10.1016/j.ijsu.2020.04.018
- 326 [2] Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease
327 2019 in China. *N Engl J Med.* 2020;382(18):1708-1720.
328 doi:10.1056/NEJMoa2002032
- 329 [3] Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical
330 Characteristics of Coronavirus Disease 2019 (COVID-19). *J Gen Intern Med.*
331 2020;35(5):1545-1549. doi:10.1007/s11606-020-05762-w
- 332 [4] Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors
333 for Delayed Return to Usual Health Among Outpatients with COVID-19 in a
334 Multistate Health Care Systems Network - United States, March-June
335 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(30):993-998. Published 2020
336 Jul 31. doi:10.15585/mmwr.mm6930e1
- 337 [5] Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study
338 Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA.*
339 2020;324(6):603-605. doi:10.1001/jama.2020.12603
- 340 [6] Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus
341 disease (COVID-19) outbreak. *J Autoimmun.* 2020;109:102433.
342 doi:10.1016/j.jaut.2020.102433
- 343 [7] Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With
344 Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional,
345 Multicenter Study. *Am J Gastroenterol.* 2020;115(5):766-773.

- 346 doi:10.14309/ajg.0000000000000620
- 347 [8] Larsen JR, Martin MR, Martin JD, Kuhn P, Hicks JB. Modeling the Onset of
348 Symptoms of COVID-19. *Front Public Health*. 2020;8:473. Published 2020 Aug
349 13. doi:10.3389/fpubh.2020.00473
- 350 [9] Speth MM, Singer-Cornelius T, Oberle M, Gengler I, Brockmeier SJ, Sedaghat
351 AR. Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19:
352 Prevalence, Severity, Timing, and Associated Characteristics. *Otolaryngol Head
353 Neck Surg*. 2020;163(1):114-120. doi:10.1177/0194599820929185
- 354 [10] Karni N, Klein H, Asseo K, et al. Self-rated smell ability enables highly specific
355 predictors of COVID-19 status: a case control study in Israel. Preprint.
356 medRxiv. 2020;2020.07.30.20164327. Published 2020 Aug 01.
357 doi:10.1101/2020.07.30.20164327
- 358 [11] Parma V, Ohla K, Veldhuizen MG, et al. More than smell - COVID-19 is
359 associated with severe impairment of smell, taste, and chemesthesis
360 [published online ahead of print, 2020 Jun 20]. *Chem Senses*. 2020;bjaa041.
361 doi:10.1093/chemse/bjaa041
- 362 [12] Gerkin RC, Ohla K, Veldhuizen MG, et al. Recent smell loss is the best predictor
363 of COVID-19: a preregistered, cross-sectional study. Preprint. medRxiv.
364 2020;2020.07.22.20157263. Published 2020 Jul 26.
365 doi:10.1101/2020.07.22.20157263
- 366 [13] Spinato G, Fabbri C, Polesel J, et al. Alterations in Smell or Taste in Mildly
367 Symptomatic Outpatients With SARS-CoV-2 Infection. *JAMA*.
368 2020;323(20):2089-2090. doi:10.1001/jama.2020.6771
- 369 [14] Sakalli E, Temirbekov D, Bayri E, Alis EE, Erdurak SC, Bayraktaroglu M. Ear nose

- 370 throat-related symptoms with a focus on loss of smell and/or taste in COVID-
371 19 patients [published online ahead of print, 2020 Jun 23]. *Am J Otolaryngol*.
372 2020;41(6):102622. doi:10.1016/j.amjoto.2020.102622
- 373 [15] Gorzkowski V, Bevilacqua S, Charmillon A, et al. Evolution of Olfactory
374 Disorders in COVID-19 Patients [published online ahead of print, 2020 Jul
375 2]. *Laryngoscope*. 2020;10.1002/lary.28957. doi:10.1002/lary.28957
- 376 [16] Yan CH, Prajapati DP, Ritter ML, DeConde AS. Persistent Smell Loss Following
377 Undetectable SARS-CoV-2 [published online ahead of print, 2020 Jun
378 9]. *Otolaryngol Head Neck Surg*. 2020;194599820934769.
379 doi:10.1177/0194599820934769
- 380 [17] Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics,
381 discharge rate, and fatality rate of meta-analysis. *J Med Virol*. 2020;92(6):577-
382 583. doi:10.1002/jmv.25757
- 383 [18] Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3062 COVID-19 patients: A
384 meta-analysis [published online ahead of print, 2020 Apr 15]. *J Med Virol*.
385 2020;10.1002/jmv.25884. doi:10.1002/jmv.25884
- 386 [19] Lee Y, Min P, Lee S, Kim SW. Prevalence and Duration of Acute Loss of Smell or
387 Taste in COVID-19 Patients. *J Korean Med Sci*. 2020;35(18):e174. Published
388 2020 May 11. doi:10.3346/jkms.2020.35.e174
- 389 [20] Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-
390 acute covid-19 in primary care. *BMJ*. 2020;370:m3026. Published 2020 Aug 11.
391 doi:10.1136/bmj.m3026
- 392

393 **LIST OF ABBREVIATIONS**

394 CDC - Centers for Disease Control and Prevention

395 SARS-CoV-2 - Severe Acute Respiratory Syndrome Coronavirus 2

396 SD - Standard Deviation

397 GCCR - Global Consortium for Chemosensory Research

398 RT-PCR – Real Time Polymerase Chain Reaction

399 URI -Upper Respiratory tract Infections

400

401 **Ethics approval**

402 The study was conducted in accordance with Helsinki committee and the required
403 ethics approval was granted (reference number HMO-0236-20).

404

405 **Ethics, consent, and permissions**

406 Written informed consents for publication of patients' clinical details were obtained
407 from the patients

408

409 **TRANSPARECY DECLARATION**

410 **Competing interests**

411 The authors declare that they have no competing interests.

412

413 **Funding**

414 MYN is supported by Israel Science Foundation (ISF) grant #1129/19. HK is a recipient
415 of the Uri Zehavi Scholarship.

416

417 **Acknowledgements**

418 We thank the Global Consortium for Chemosensory Research (GCCR) team for
419 inspiring the questionnaire used in this research. We thank Yehuda Tarnovsky for help
420 with patient's recruitment.

421